Release issued 4th April 2001

York, UK - Pharmalicensing announces today that Argus Insights, a full-service market research firm that conducts market assessments for emerging technologies in the biological, material, computer and physical sciences has rated pharmalicensing.com highest among online intellectual property (IP) exchange sites for the life science industry.

Pharmalicensing, received a ranking of 45 points out of 50-- the highest ranking among the Internet's most prominent life science sites.

In their latest report, IP Sites 2001, Argus ranked life science IP exchange sites on functionality, number of participants, durability, business model and performance. Pharmalicensing.com consistently received higher scores than most of its competitors in all categories. The Argus report praised pharmalicensing for its valuable company profiles, diversity of revenue streams and impressive number of deals completed. Additional comments included, "excellent industry information, detailed technology descriptions and high web traffic."

Unlike most of its competitors, pharmalicensing has reached profitability with its diversified revenue stream of intelligent technology listings, solution directories, company profiles and solution-oriented advertisements.

"We certainly appreciate the recognition of our efforts by such a well-respected research organization as Argus Insights," stated Steve Poile, Vice President Business & Product Development of pharmalicensing. "We will continue our pace of execution to ensure that our customers are offered a total solution when developing and commercializing their Life Science IP."

About pharmalicensing Ltd (www.pharmalicensing.com)

Pharmalicensing is the definitive resource for business development in the pharmaceutical and medical industry.

(4th January 2008) UTEK Corporation Acquires Pharmalicensing, Ltd.

(25th July 2007) Pharmalicensing launches 3rd edition of top selling licensing agreement report

(23rd July 2007) Comprehensive consultancy support for your licensing

(15th January 2007) New report from Pharmalicensing highlights the R&D opportunities in China

(1st December 2006) Pharmalicensing's latest report reveals new early stage dealmaking trends